0.50 / AMA PRA Category 1 Credit(s)TM 0.50 / ABIM MOC Point
An important note about ABIM MOC Part II points Successful completion of this CME activity enables eligible participants to earn up to 0.50 ABIM-Part II Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. To claim MOC points, follow these easy steps:
Step 1: Complete all 3 questions under the "ABIM Part 2 Credit Questions" section, located at the bottom of the course evaluation form. This includes 1) attesting that our partner may submit your credits to ABIM, 2) attesting that you are ABIM board certified, 3) providing your ABIM #, and 4) providing your date of birth (MM/DD).
Step 2: Our partner, The University of Cincinnati, will send your MOC points to your ABIM account within 6-8 weeks.
Provided by University of Cincinnati
Supported by educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals and Novartis Pharmaceutical Corporation
Despite advances in understanding the drivers of severe asthma, rates of hospitalization and mortality due to asthma have not changed significantly in the last two decades. It’s only recently as the medical community has become better at identifying specific asthma endotypes and phenotypes that we’ve seen the rise of unique therapies targeting specific disease pathways. This activity will break down the differences between Type 2 and non-Type 2 asthma and discuss how making that differentiation in severe asthma patients has a profound impact on treatment pathways.
Pulmonologists, allergists, primary care physicians (PCPs), NPs, PAs and other healthcare providers who manage patients with severe asthma
After completing this activity, the participant will demonstrate the ability to:
Review the benefits and limitations of traditional asthma therapy (eg, ICS, LABAs, LAMAs, and LTRAs) for severe asthma phenotypes/endotypes.
Compare new and emerging phenotype/endotype-targeted agents for severe asthma.
Develop individualized treatment plans for patients with severe uncontrolled asthma.
Emily DiMango, MD Professor of Medicine Director, John Edsall-John Wood Asthma Center Columbia University Medical Center New York, New York
Dr. DiMango discloses the following: Advisory Board: AstraZeneca
Michael E. Wechsler, MD, MMSc Professor of Medicine Director, NJH Cohen Family Asthma Institute Division of Pulmonary, Critical Care & Sleep Medicine National Jewish Health Denver, CO
Susan P. Tyler, MEd, CMP, CHCP, CME Director, University of Cincinnati, has no conflicts of interest to disclose. Bruce C. Gebhardt, MD, CME Reviewer-Compliance, University of Cincinnati, has no conflicts of interest to disclose. Heather Muskopf, Program Manager, Continuing Medical Education, University of Cincinnati, has no conflicts of interest to disclose.
Publishing Staff Disclosures
The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material activity for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (from ABIM):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Unlabeled Use
The credit providers require all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the University of Cincinnati Continuing Medical Education Department at email@example.com or call 513-558-7277.